The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

About 3,500 adults across 28 countries were enrolled in the trial, which started in 2019 and followed participants for an ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

There's growing evidence to suggest that GLP-1 drugs, which include semaglutide, may be useful for treating alcohol use disorder.

There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

Drug manufacturer Novo Nordisk's amycretin, an experimental weight-loss pill in clinical trials, may boast substantial weight ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...

WEIGHT-loss jabs are taking the world by storm, with a staggering half a million of us now using them. The injections have ...

This compares to clinical trials of Ozempic (semaglutide), where during the same period, participants lost an average of around 15 percent of their body weight. Jane suspects the unpleasant side ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...